Why patellofemoral OA is a distinct diagnosis

Front-of-knee pain after climbing stairs, or that aching stiffness after sitting through a film — these are not random complaints. They point to a specific part of the knee: the joint formed between the kneecap (patella) and the groove at the base of the femur (the trochlea). When the cartilage lining that surface wears down, the condition is patellofemoral osteoarthritis (PFOA), and it is a distinct diagnosis from the more widely discussed 'inner knee' or 'outer knee' arthritis affecting the tibiofemoral compartments.

The cartilage on the underside of the patella has no blood supply of its own, which means it cannot repair itself once degenerative change takes hold. Early softening can remain stable for years, but once the process progresses, the trajectory tends to worsen rather than reverse.

Why the distinction matters: the symptom pattern, the imaging approach, and the treatment decisions for PFOA differ meaningfully from generalised knee arthritis. Many patients are told only that they have 'knee arthritis' — without compartment identification — which can lead to a management plan that misses the specific mechanical and structural drivers at the front of the knee.

Symptoms and how they present

Stair descent tends to be the sharpest trigger — many people find going down harder than going up, because the patellofemoral joint absorbs load across a greater arc of flexion on each step. Squatting and kneeling provoke similar discomfort, and a pattern known as the 'cinema sign' describes the ache that builds during prolonged sitting with the knee bent, often prompting people to straighten the leg mid-film or rise stiffly after a long car journey.

The pain comes on gradually rather than following a single injury. Most people look back and notice it creeping in over months — initially only on demanding activities, then on ordinary tasks such as climbing a flight of stairs at home or getting out of a low chair.

Crepitus — a grinding, grating, or clicking sensation felt or heard beneath the kneecap — is common and often appears before pain becomes consistent. It reflects surface irregularity in the cartilage, but on its own it is not a reliable indicator of how severe things are; some people with audible crepitus have manageable symptoms, while others with less noise report significant discomfort.

Symptoms rarely decline in a smooth, steady way. A more typical pattern is a relative plateau over several months, punctuated by flares that can seem disproportionate to recent activity levels. Pain at rest or at night may suggest more advanced cartilage loss or bone marrow involvement and is a reasonable prompt to seek specialist assessment.

What drives the problem — mechanical factors behind PFOA

Cartilage wear in PFOA is rarely uniform — it concentrates where contact pressure is highest, and that pressure is shaped by how well the kneecap tracks through the femoral groove as the knee bends and straightens.

Several mechanical factors determine that tracking. The vastus medialis oblique (VMO), the inner portion of the quadriceps, acts as the primary medial stabiliser of the patella; when it is relatively weak, the kneecap tends to drift laterally under load, pressing harder against one facet of the trochlea than the other. Hip abductor weakness compounds this by allowing the thigh to rotate inward during weight-bearing, which increases lateral patellar loading further up the chain. A high Q-angle — the angular relationship between the hip, kneecap, and shin that is typically wider in people with a broader pelvis or knock-knee tendency — and flat-foot pronation both add to these contact forces from below.

These factors matter clinically because they are modifiable. Targeted rehabilitation that restores VMO activation, hip abductor strength, and load distribution across the lower limb addresses the underlying mechanism of cartilage overload — not merely its symptoms. Identifying which drivers are present in a given patient is therefore one of the central tasks of a structured assessment.

What assessment involves

A specialist assessment typically moves through three levels: hands-on examination, plain X-ray, and MRI — each adding information the previous step cannot provide.

During the physical examination, the clinician will palpate around the kneecap and joint line to locate tenderness, assess how the patella moves through its groove under gentle pressure (patellar tracking), and measure the Q-angle. Full range of motion is recorded, and ligamentous stability testing — including varus and valgus stress at different degrees of flexion, and a Lachman test — rules out other sources of pain that may coexist or mimic patellofemoral symptoms.

Weight-bearing plain X-ray is generally the next step. It is straightforward and widely available, and can confirm joint-space narrowing and osteophyte formation at the patellofemoral joint. Its main limitation is that cartilage itself is not visible on X-ray; early cartilage loss may not yet have narrowed the joint space, so a normal-looking film does not rule out significant chondral change.

MRI is the most informative tool for assessing the patellofemoral compartment directly. It allows the cartilage surface to be graded using validated systems such as WORMS (grade 3 and above indicating established morphological loss) and BLOKS (which records between 10 and 75 per cent cartilage loss in the patellofemoral region). MRI also detects bone marrow lesions (BMLs), subchondral changes that are associated with pain severity and help guide treatment decisions.

One important caveat applies to any imaging result: structural findings on MRI do not automatically translate into a need for intervention. Cartilage irregularity on a scan is common and does not, on its own, determine the next step — symptoms, functional impact, and examination findings are interpreted alongside it.

Arthroscopic grading using the ICRS classification (grades I to IV) provides the most precise picture of cartilage morphology but is reserved for situations where surgical decision-making is actively being considered, not as a routine diagnostic step. Taken together, the assessment informs which rung of the treatment ladder is the appropriate starting point.

Rehabilitation as the essential first step

Structured rehabilitation is the foundation of PFOA management — not a waiting room before injections, but the intervention most likely to change the underlying loading pattern driving cartilage wear.

A well-designed programme targets the mechanical contributors identified at assessment: VMO and broader quadriceps activation, hip abductor strengthening to control femoral rotation during weight-bearing, and neuromuscular control through the full arc of flexion. Patellar taping or a patellofemoral brace is often added in the early weeks to reduce compressive forces while muscle strength is building — a practical measure that allows patients to stay active rather than avoiding movement altogether. Where flat-foot pronation is contributing to patellofemoral load, foot orthoses may be recommended alongside the exercise programme.

Activity modification runs in parallel: temporarily reducing high-load triggers — deep squats, stair repetitions, prolonged kneeling — gives symptoms room to settle without abandoning exercise entirely. Most patients see meaningful improvement within eight to twelve weeks of consistent, supervised rehabilitation.

Incomplete or poorly supervised rehabilitation is one of the most common reasons symptoms persist. If the underlying muscle imbalance or tracking problem remains uncorrected, any subsequent injection is working against an unresolved mechanical disadvantage and is unlikely to produce durable relief. Injections are therefore considered once a patient has worked through a structured programme and functional improvement has reached a plateau.

Injection options and what the evidence says

Four injection categories are available for patients whose symptoms persist despite adequate rehabilitation. Each acts differently and carries a distinct evidence base — but none reverses structural cartilage change; the aim is symptom management and, where possible, slowing further deterioration.

Corticosteroid injections act rapidly by suppressing intra-articular inflammation, typically producing meaningful pain relief within days. Benefit is generally short-term, with most estimates suggesting effects plateau by around three months. Evidence indicates that repeated corticosteroid injections may have adverse effects on cartilage structure over time, so they are most appropriate for managing acute inflammatory flares rather than as a recurring strategy.

Hyaluronic acid (viscosupplementation) — products include Durolane, Ostenil, Monovisc, Synvisc, and Cingal — restores the viscoelastic properties of synovial fluid, improving lubrication and joint cushioning. A systematic review of 11 studies found no consistent advantage of multi-injection regimens over single-injection formulations for patient-reported outcomes. Evidence supports meaningful pain reduction and may delay the need for surgical intervention. A caveat that applies across all four categories: most injection trials enrolled general knee OA populations with tibiofemoral distribution; the evidence in PFOA specifically is largely extrapolated rather than compartment-confirmed.

PRP (platelet-rich plasma) is used clinically in patellofemoral cartilage conditions and is listed alongside hyaluronic acid as an injection option at this stage. The PFOA-specific RCT evidence base is currently less developed than for hyaluronic acid or corticosteroid, and this gap should inform realistic expectations.

Arthrosamid® (iPAAG — intra-articular polyacrylamide hydrogel) is the most emerging option with direct patellofemoral evidence. A 2022 study (Maulana et al, Journal of Arthritis) demonstrated reduction in patellofemoral bone marrow lesions following a single injection in advanced PFOA. A 12-month open-label follow-up (Bliddal et al, J Orthop Surg Res, 2024) confirmed sustained safety and effectiveness for knee OA broadly, supporting durability from a single-injection protocol.

A reasonable candidate for injection has three features in common: imaging that confirms patellofemoral distribution, absence of contraindications such as active infection or coagulopathy, and a structured rehabilitation programme already completed. Where underlying mechanical contributors remain unaddressed, the benefit of any injection is likely to be short-lived.

1. [1] Patellofemoral pain syndrome — Wikipedia. https://en.wikipedia.org/?curid=12033023 https://en.wikipedia.org/?curid=12033023
2. [2] Joint injection — Wikipedia. https://en.wikipedia.org/?curid=1425459 https://en.wikipedia.org/?curid=1425459